- Home
- PCRX vs SMBK Comparison
PCRX vs SMBK Comparison
Compare PCRX & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- SMBK
- Stock Information
- Founded
- PCRX 2006
- SMBK N/A
- Country
- PCRX United States
- SMBK United States
- Employees
- PCRX N/A
- SMBK N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- SMBK Major Banks
- Sector
- PCRX Health Care
- SMBK Finance
- Exchange
- PCRX Nasdaq
- SMBK Nasdaq
- Market Cap
- PCRX 1.2B
- SMBK 553.9M
- IPO Year
- PCRX 2011
- SMBK N/A
- Fundamental
- Price
- PCRX $22.73
- SMBK $35.23
- Analyst Decision
- PCRX Buy
- SMBK Buy
- Analyst Count
- PCRX 8
- SMBK 5
- Target Price
- PCRX $28.38
- SMBK $34.40
- AVG Volume (30 Days)
- PCRX 492.0K
- SMBK 66.6K
- Earning Date
- PCRX 07-29-2025
- SMBK 07-21-2025
- Dividend Yield
- PCRX N/A
- SMBK 0.91%
- EPS Growth
- PCRX N/A
- SMBK 44.84
- EPS
- PCRX N/A
- SMBK 2.26
- Revenue
- PCRX $702,772,000.00
- SMBK $171,664,000.00
- Revenue This Year
- PCRX $7.92
- SMBK $20.95
- Revenue Next Year
- PCRX $11.02
- SMBK $9.48
- P/E Ratio
- PCRX N/A
- SMBK $15.53
- Revenue Growth
- PCRX 3.08
- SMBK 16.34
- 52 Week Low
- PCRX $11.16
- SMBK $25.41
- 52 Week High
- PCRX $27.64
- SMBK $37.72
- Technical
- Relative Strength Index (RSI)
- PCRX 36.58
- SMBK 70.82
- Support Level
- PCRX $22.23
- SMBK $35.04
- Resistance Level
- PCRX $23.91
- SMBK $35.99
- Average True Range (ATR)
- PCRX 0.82
- SMBK 0.73
- MACD
- PCRX -0.01
- SMBK 0.12
- Stochastic Oscillator
- PCRX 22.03
- SMBK 94.44
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.